M
Mervi Jumppanen
Researcher at University of Tampere
Publications - 8
Citations - 1137
Mervi Jumppanen is an academic researcher from University of Tampere. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 6, co-authored 8 publications receiving 1074 citations.
Papers
More filters
Journal ArticleDOI
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67
TL;DR: It is anticipated that free web applications, such as ImmunoRatio, will make the quantitative image analysis of ER, PR, and Ki-67 easy and straightforward in the diagnostic assessment of breast cancer specimens.
Journal ArticleDOI
Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repair
Lao H. Saal,Sofia K. Gruvberger-Saal,Camilla Persson,Kristina Lövgren,Mervi Jumppanen,Johan Staaf,Göran Jönsson,Maira M. Pires,Matthew Maurer,Karolina Holm,Susan Koujak,Shivakumar Subramaniyam,Johan Vallon-Christersson,Håkan Olsson,Tao Su,Lorenzo Memeo,Thomas Ludwig,Stephen P. Ethier,Morten Krogh,Matthias Szabolcs,Vundavalli V. Murty,Jorma Isola,Hanina Hibshoosh,Ramon Parsons,Åke Borg +24 more
TL;DR: It is shown that heterozygous inactivation of the tumor suppressor gene Pten leads to the formation of basal-like mammary tumors in mice, and that loss of PTEN expression is significantly associated with the BBC subtype in human sporadic and BRCA1-associated hereditary breast cancers.
Journal ArticleDOI
Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers
Mervi Jumppanen,Sofia K. Gruvberger-Saal,Päivikki Kauraniemi,Minna Tanner,Pär-Ola Bendahl,Mikael Lundin,Morten Krogh,Pasi Kataja,Åke Borg,Mårten Fernö,Jorma Isola +10 more
TL;DR: Basal cytokeratin-positive tumors have a biologically distinct gene expression signature from other ER-negative tumors, and the clinical outcome of basal tumors is similar to non-basal ER- negative tumors.
Journal ArticleDOI
Integrated molecular pathway analysis informs a synergistic combination therapy targeting PTEN/PI3K and EGFR pathways for basal-like breast cancer
Qing-Bai She,Qing-Bai She,Sofia K. Gruvberger-Saal,Sofia K. Gruvberger-Saal,Matthew Maurer,Yilun Chen,Mervi Jumppanen,Tao Su,Meaghan Dendy,Ying Ka Ingar Lau,Lorenzo Memeo,Hugo M. Horlings,Marc J. van de Vijver,Jorma Isola,Hanina Hibshoosh,Neal Rosen,Ramon Parsons,Lao H. Saal,Lao H. Saal +18 more
TL;DR: This study emphasizes the importance of PI3K/PTEN pathway activity in ER-negative and basal-like breast cancer and supports the future clinical evaluation of combining EGFR andPI3K pathway inhibitors for the treatment of BLBC.
Journal ArticleDOI
Aurora-A gene is frequently amplified in basal-like breast cancer.
TL;DR: Assessment of the clinicopathological associations of AURKA gene amplification in clinical breast tumors and association of gene copy number with its mRNA and protein expression in breast cancer cell lines finds patients suitable candidates for future targeted therapies with Aurora-A inhibitors.